Pertuzumab for the treatment of breast cancer: a safety review
Author:
Affiliation:
1. Department of Medical Oncology Service, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, USA
2. Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, USA
Publisher
Informa Healthcare
Subject
Pharmacology (medical),General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1517/14740338.2016.1167185
Reference46 articles.
1. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
2. The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
3. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
4. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
5. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS);BMC Pharmacology and Toxicology;2023-11-13
2. Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2‐positive cancers;Molecular Oncology;2023-03-27
3. Pertuzumab Charge Variant Analysis and Complementarity-Determining Region Stability Assessment to Deamidation;ANAL CHEM;2023
4. Pertuzumab Charge Variant Analysis and Complementarity-Determining Region Stability Assessment to Deamidation;Analytical Chemistry;2023-02-16
5. Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis;Investigational New Drugs;2022-05-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3